Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 1/2012

01-02-2012 | Original Paper

Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy

Authors: O. Zaniolo, S. Iannazzo, L. Pradelli, M. Miravitlles

Published in: The European Journal of Health Economics | Issue 1/2012

Login to get access

Abstract

The randomized, double-blind trial UPLIFT® demonstrated in 5,993 patients with moderate to very severe COPD that 4 years of tiotropium bromide therapy were associated with improvements in lung function, exacerbations, quality of life, and mortality compared with placebo. The pharmacoeconomic evaluation was performed through a probabilistic, patient-level simulation Markov model. Routine COPD care (RC) was compared with the inclusion of tiotropium bromide on it. The analysis was conducted over a lifetime horizon, with 1 year cycles and a 3.5% annual discount rate. Patients were characterized by gender, age, height, smoking status, and forced expiratory volume in 1 s (FEV1). FEV1 time trend was modeled according to the annual decline recorded in UPLIFT®. Mortality derived from that of the general Italian population was adjusted by smoking status and FEV1. Health utilities derived from published Italian observational studies and were varied in time according to UPLIFT® data. Exacerbation rates were derived from a published Italian observational prospective study. The cost perspective was that of the Italian National Health Service. Healthcare resource consumption for RC and exacerbations derived from Italian observational studies were valued according to current price and tariffs. Simulated patients in the tiotropium arm gained an average (95% CI) 0.50 (−1.63 to 6.27) Life Years (LYs) and 0.42 (−0.25 to 3.05) Quality-Adjusted Life Years (QALYs). The incremental lifetime cost resulted €3,357 (−€10,669 to €29,820). The incremental cost-effectiveness ratio (ICER) was €6,698/LY and €7,916/QALY. In the cost-effectiveness acceptability curve (CEAC), tiotropium had a 90% probability of being cost-effective for a willingness to pay (WTP) threshold of € 10,000/QALY.
Literature
1.
WHO—World Health Organization: World health report. WHO, Geneva (2000)
2.
Stang, P., Lydick, E., Silberman, C., Kempel, A., Keating, E.T.: The prevalence of COPD: using smoking rates to estimate disease frequency in the general population. Chest 117, 354S–359S (2000)PubMedCrossRef
3.
Feenstra, T.L., van Genugten, M.L., Hoogenveen, R.T., Wouters, E.F., Rutten-van Mölken, M.P.: The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am. J. Respir. Crit. Care Med. 164, 590–596 (2001)PubMed
4.
Oostenbrink, J.B., Rutten-van Mölken, M.P.M.H.: Resource use and risk factors in high-cost exacerbations of COPD. Respir. Med. 98, 883–891 (2004)PubMedCrossRef
5.
Miravitlles, M., Murio, C., Guerrero, T., Gisbert, R.: Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 123, 784–791 (2003)PubMedCrossRef
6.
Andersson, F., Borg, S., Jansson, S.A., Jonsson, A.C., Ericsson, A., Prütz, C., Rönmark, E., Lundbäck, B.: The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir. Med. 96, 700–708 (2002)PubMedCrossRef
7.
Dal Negro, R., Rossi, A., Cerveri, I.: The burden of COPD in Italy: results from the Confronting COPD survey. Respir. Med. 97(Suppl C), S43–S50 (2003)PubMedCrossRef
8.
Koleva, D., Motterlini, N., Banfi, P., Garattini, L.: Healthcare costs of COPD in Italian referral centres: a prospective study. Respir. Med. 101, 2312–2320 (2007)PubMedCrossRef
9.
Lucioni, C., Donner, C., De Benedetto, F., Lusuardi, M., Mazzi, S., Paggiaro, P., Sanguinetti, C.: I costi della broncopneumopatia cronica ostruttiva: la fase prospettica dello Studio ICE (Italian Costs for Exacerbations in COPD). PharmacoEconomics—Italian Research Articles 7, 119–134 (2005)
10.
Casaburi, R., Mahler, D.A., Jones, P.W., Wanner, A., San, P.G., ZuWallack, R.L., Menjoge, S.S., Serby, C.W., Witek, T.J.: A long-term evaluation of once-daily inhaled tiotropium bromide in chronic obstructive pulmonary disease. Eur. Respir. J. 19, 217–224 (2002)PubMedCrossRef
11.
Vincken, W., van Noord, J.A., Greefhorst, A.P.M., Bantje, T.A., Kesten, S., Korducki, L., Cornelissen, P.J.G.: Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium bromide. Eur. Respir. J. 19, 209–216 (2002)PubMedCrossRef
12.
Brusasco, V., Hodder, R., Miravitlles, M., Korducki, L., Towse, L., Kesten, S.: Health outcomes following treatment for six months with once daily tiotropium bromide compared with twice daily salmeterol in patients with COPD. Thorax 58, 399–404 (2003)PubMedCrossRef
13.
Tashkin, D.P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S., Decramer, M.: A 4-year trial of tiotropium bromide in chronic obstructive pulmonary disease. N. Engl. J. Med. 359, 1543–1554 (2008)PubMedCrossRef
14.
Dal Negro, R.W., Tognella, S., Tosatto, R., Dionisi, M., Turco, P., Donner, C.F.: Costs of chronic obstructive pulmonary disease (COPD) in Italy: the SIRIO study (social impact of respiratory integrated outcomes). Respir. Med. 102, 92–101 (2008)PubMedCrossRef
15.
Antonelli-Incalzi, R., Imperiale, C., Bellia, V., Catalano, F., Scichilone, N., Pistelli, R., Rengo, F.: Do GOLD stages of COPD severity really correspond to differences in health status? Eur. Respir. J. 22, 444–449 (2003)PubMedCrossRef
16.
Aaron, S.D., Vandemheen, K.L., Fergusson, D., Maltais, F., Bourbeau, J., Goldstein, R., Balter, M., O’Donnell, D., McIvor, A., Sharma, S., Bishop, G., Anthony, J., Cowie, R., Field, S., Hirsch, A., Hernandez, P., Rivington, R., Road, J., Hoffstein, V., Hodder, R., Marciniuk, D., McCormack, D., Fox, G., Cox, G., Prins, H.B., Ford, G., Bleskie, D., Doucette, S., Mayers, I., Chapman, K., Zamel, N., FitzGerald, M.: Tiotropium bromide in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 146, 545–555 (2007)PubMed
17.
Borrill, Z.L., Houghton, C.M., Tal-Singer, R., Vessey, S.R., Faiferman, I., Langley, S.J., Singh, D.: The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD. Br. J. Clin. Pharmacol. 65, 244–252 (2008)PubMedCrossRef
18.
Freeman, D., Lee, A., Price, D.: Efficacy and safety of tiotropium bromide in COPD patients in primary care—the SPiRiva Usual CarE (SPRUCE) study. Respir Res 8, 45 (2007)PubMedCrossRef
19.
Verkindre, C., Bart, F., Aguilaniu, B., Fortin, F., Guérin, J., Le Merre, C., Iacono, P., Huchon, G.: The effect of tiotropium bromide on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration 73, 420–427 (2006)PubMedCrossRef
20.
Maltais, F., Hamilton, A., Marciniuk, D., Hernandez, P., Sciurba, F.C., Richter, K., Kesten, S., O’Donnell, D.: Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium bromide in patients with COPD. Chest 128, 1168–1178 (2005)PubMedCrossRef
21.
Niewoehner, D.E., Rice, K., Cote, C., Paulson, D., Cooper, J.A.D.J., Korducki, L., Cassino, C., Kesten, S.: Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium bromide, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann. Intern. Med. 143, 317–326 (2005)PubMed
22.
O’Donnell, D.E., Flüge, T., Gerken, F., Hamilton, A., Webb, K., Aguilaniu, B., Make, B., Magnussen, H.: Effects of tiotropium bromide on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur. Respir. J. 23, 832–840 (2004)PubMedCrossRef
23.
van Noord, J.A., Aumann, J.L., Janssens, E., Verhaert, J., Smeets, J.J., Mueller, A., Cornelissen, P.J.G.: Effects of tiotropium bromide with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 129, 509–517 (2006)PubMedCrossRef
24.
25.
26.
Lange, P., Nyboe, J., Appleyard, M., Jensen, G., Schnohr, P.: Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. Thorax 45, 579–585 (1990)PubMedCrossRef
27.
Ståhl, E., Lindberg, A., Jansson, S., Rönmark, E., Svensson, K., Andersson, F., Löfdahl, C., Lundbäck, B.: Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 3, 56 (2005)PubMedCrossRef
28.
Ferrario, M.M., Fornari, C., Bolognesi, L., Gussoni, M.T., Benedetti, M., Sega, R., Borchini, R., Cesana, G.: Recent time trends of myocardial infarction rates in northern Italy. Results from the MONICA and CAMUNI registries in Brianza: 1993–1994 versus 1997–1998. Ital. Heart J. Suppl. 4, 651–657 (2003)
29.
ANMCO Consensus Conference.: Il percorso assistenziale del paziente con scompenso cardiaco. G. Ital. Cardiol. Giugno 7 (2006)
30.
Sidney, S., Sorel, M., Quesenberry, C.P.J., DeLuise, C., Lanes, S., Eisner, M.D.: COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser permanente medical care program. Chest 128, 2068–2075 (2005)PubMedCrossRef
31.
Italian Specialist Tariffs. Nomenclatore Tariffario Nazionale D.M. 22 luglio 1996
32.
Nomenclatore Tariffario Nazionale: DRG Tariffs. DMS 12/09/2006. Supplemento Ordinario alla Gazzetta Ufficiale n. 289 del 13/12/2006
33.
34.
Italian Drug Formulary: Informatore Farmaceutico, 69a edizione. Elsevier Masson (2009)
35.
36.
Laupacis, A., Feeny, D., Detsky, A.S., Tugwell, P.X.: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146, 473–481 (1992)PubMed
37.
Tosteson, A.N.: Quality of life in the economic evaluation of osteoporosis prevention and treatment. Spine (Phila Pa 1976) 22:58S–62S (1997)
38.
Kanis, J.A., Jonsson, B.: Economic evaluation of interventions for osteoporosis. Osteoporos. Int. 13, 765–767 (2002)PubMedCrossRef
39.
Raftery, J.: NICE: faster access to modern treatments? Analysis of guidance on health technologies. Br Med J 323, 1300–1303 (2001)CrossRef
40.
41.
Oostenbrink, J.B., Rutten-van Mölken, M.P.M.H., Monz, B.U., FitzGerald, J.M.: Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 8, 32–46 (2005)PubMedCrossRef
42.
Rutten-van Mölken, M.P.M.H., Oostenbrink, J.B., Miravitlles, M., Monz, B.U.: Modelling the 5-year cost effectiveness of tiotropium bromide, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ 8, 123–135 (2007)PubMedCrossRef
43.
Maniadakis, N., Tzanakis, N., Fragoulakis, V., Hatzikou, M., Siafakas, N.: Economic evaluation of tiotropium bromide and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece. Curr. Med. Res. Opin. 22, 1599–1607 (2006)PubMedCrossRef
44.
Nishimura S, Kobayashi M, Hasegawa T.: Cost-effectiveness analysis of tiotropium bromide for chronic obstructive pulmonary disease (COPD) patients in Japan. ISPOR 10th Annual International Meeting, 2005. Washington, DC, USA
45.
Brosa, M., Díaz, S., Miravitlles, M., Gonzalez-Rojas, N., Nieves, D.: Cost-effectiveness analysis of tiotropium bromide in the treatment of chronic obstructive pulmonary disease (COPD) patients in Spain. ISPOR 12th Annual European Congress, 2009. Paris, France
46.
De Lucas, P., Rodríguez, J., Gobartt, E., Soto, J., Martin, A.: Pharmacoeconomic evaluation of tiotropium bromide in the treatment of patients with chronic obstructive pulmonary disease in Spain. ISPOR 8th European Congress, 2005. Florence, Italy
47.
Onukwugha, E., Mullins, C.D., DeLisle, S.: Using cost-effectiveness analysis to sharpen formulary decision-making: the example of tiotropium bromide at the veterans affairs health care system. Value Health 11, 980–988 (2008)PubMedCrossRef
48.
Schramm, W., Haake, D., Brandt, A.: Economic value of tiotropium bromide in the treatment of chronic obstructive pulmonary disease. Praxis (Bern 1994) 94:1803–1810 (2005)
49.
Lee, K., Phua, J., Lim, T.: Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore. Respir. Med. 100, 2190–2196 (2006)PubMedCrossRef
50.
Oba, Y.: Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD. Am J Manag Care 15, 226–232 (2009)PubMed
51.
Earnshaw, S.R., Wilson, M.R., Dalal, A.A., Chambers, M.G., Jhingran, P., Stanford, R., Mapel, D.W.: Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. Respir. Med. 103, 12–21 (2009)PubMedCrossRef
52.
Spencer, M., Briggs, A.H., Grossman, R.F., Rance, L.: Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 23, 619–637 (2005)PubMedCrossRef
53.
Miravitlles, M., Murio, C., Guerrero, T., Gisbert, R.: Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 121, 1449–1455 (2002)PubMedCrossRef
54.
Ram, F.S.F., Wedzicha, J.A., Wright, J., Greenstone, M.: Hospital at home for patients with acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence. BMJ 329, 315 (2004)PubMedCrossRef
55.
Jahnz-Rozyk, K.M., Targowski, T., From, S.: Costs of COPD exacerbations in Poland (results of the pilot study). ISPOR 9th Annual European Congress. Copenhagen, Denmark
56.
Spannheimer, A., Schlegel, C., Reitberger, U., Welsch, R., Ruckdaeschel, S.: Costs of COPD in Germany—results of a cost-of illness study. ISPOR 6th Annual European Congress. Barcelona, Spain
57.
Halpin, D.M.G., Miravitlles, M.: Chronic obstructive pulmonary disease. The Disease and Its Burden to Society. Proc Am Thorac Soc 3, 619–623 (2006)PubMedCrossRef
58.
Seemungal, T.A.R., Hurst, J.R., Wedzicha, J.A.: Exacerbation rate, health status and mortality in COPD–a review of potential interventions. Int J Chron Obstruct Pulmon Dis 4, 203–223 (2009)PubMed
59.
FitzGerald, J.M., Haddon, J.M., Bradly-Kennedy, C., Kuramoto, L., Ford, G.T.: Resource use study in COPD (RUSIC): a prospective study to quantify the effects of COPD exacerbations on health care resource use among COPD patients. Can Respir J 14, 145–152 (2007)PubMed
60.
Mantovani, L.G., Mannino, S., Donner, C.E., et al.: The cost of COPD: Results from the SIRIBO (Studio Italiano sulle Riacutizzazioni Infettive delle Bronchiti). Eur. Respir. J. 20(suppl 38) (2002)
61.
Metadata
Title
Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy
Authors
O. Zaniolo
S. Iannazzo
L. Pradelli
M. Miravitlles
Publication date
01-02-2012
Publisher
Springer-Verlag
Published in
The European Journal of Health Economics / Issue 1/2012
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-010-0285-8

Other articles of this Issue 1/2012

The European Journal of Health Economics 1/2012 Go to the issue

Original Paper

Comparing the sensitivity of EQ-5D, SF-6D and 15D utilities to the specific effect of diabetic complications

Editorial

Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe?

Original Paper

The impact of presumed consent laws and institutions on deceased organ donation

Original Paper

Do smoke-free laws affect revenues in pubs and restaurants?

Original paper

Future costs in cost-effectiveness analysis: an empirical assessment

Original Paper

Decomposing the determinants of health care expenditure: the case of Spain